Bionest Partners

Bionest Partners was a leading global consulting and advisory firm specializing in strategy, management consulting, and transaction advisory for life sciences companies. It supported clients across pharma, biotech, medical devices, diagnostics with product development strategies and market access. The company was acquired by Accenture in February 2023 to expand Accenture’s capabilities in advanced therapies and precision medicine. Bionest was a global life science consultancy that advised major deals such as the Marinomed/Boehringer Ingelheim licensing agreement. Its client list included top global pharma & biotech firms. It had no internal drug/development pipeline. Bionest specialized in rare disease/gene therapy/CNS/orphan disease/commercialization/value creation/due diligence/investment banking support/outlicensing/inlicensing/M&A/private placement/IPOs/go-to-market/regulatory affairs/pricing/reimbursement analysis/business intelligence/surrogate management/global market entry support.